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ABSTRACT 
Breast cancer is one of the most common cancers in women. Estrogen receptor α (ERα) 
signaling and p53 signaling have important roles in breast cancer progression. Therefore, 
post-translational modifications of ERα and p53 play critical roles in breast cancer. The 
overall aim of this thesis is to characterize the role of RING-finger protein 31 (RNF31) on 
ERα and p53 signaling and the function of P21-activated kinase 4 (PAK4) on ERα signaling. 
Moreover, the role of PAK4 in mouse mammary development and mammary tumor 
progression was also analyzed. 
In the first study, RNF31 was shown to active and stabilize ERα, and subsequently to 
increase estrogen-stimulated cell proliferation in breast cancer cells. In breast cancer clinical 
databases, the gene expression of RNF31 and ERα target genes were correlated. The 
suggested mechanism is that RNF31 interacts ERα via the RBR domain and facilitate ERα 
mono-ubiquitination. 
In the second study, RNF31 depletion was shown to increase the gene expression of p53 
target genes. RNF31 depletion caused cycle arrest and cisplatin-induced apoptosis in a p53-
dependent manner in breast cancer cells. Depletion of RNF31 increased p53 protein levels 
and the mRNA levels of its downstream target genes. The suggested mechanism is that 
RNF31 interacts with the p53/MDM2 complex and stabilizes MDM2 and consequently 
facilitates p53 poly-ubiquitination and degradation. 
In the third study, high PAK4 expression level was correlated with poor tamoxifen response 
in breast cancer patients in clinical databases, based on analysis of available mRNA 
expression. In MCF-7 cells, PAK4 overexpression promoted tamoxifen resistance, while 
PAK4 inhibition sensitized tamoxifen-resistant breast cancer cells to tamoxifen. 
Mechanistically, we identified a regulatory positive feedback loop, where PAK4 acts as a 
downstream target gene of ERα; while PAK4 can phosphorylate ERα at Ser305, thereby 
increasing ERα protein stability and activating ERα signaling. In conclusion, PAK4 may be a 
suitable target for tamoxifen resistance in breast cancer.  
In the fourth study, we elucidated the function of PAK4 in mammary development and 
mammary tumor progression in vivo. We observed no difference in mammary gland 
development between control mice and PAK4 conditional knockout mice. To test the role of 
PAK4 in mammary tumor development, conditional depletion of PAK4 was introduced in the 
MMTV-PyMT breast cancer mouse model. Importantly, conditional PAK4 depletion caused 
an increased tumor latency in MMTV-PyMT mice, indicating a role for PAK4 in early 
mammary tumor development. 
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1 INTRODUCTION 
1.1 NEOPLASM 
The word “Neoplasm” came from Ancient Greek (neo means “new” and plasma means 
“formation”), which refers to the tissue having abnormal appearance, abnormal proliferation 
pattern and undergoing some form of mutation. In most cases, neoplasm forming a mass, it is 
commonly called tumor or solid tumor; but in few cases, neoplasm does not form a mass, 
such as in leukemia. The word “tumor” is of Latin origin and means “swelling”. It is 
noteworthy that, “tumor” is not only referring to “neoplasm”, but also referring to general 
mass. However, the two words are used as synonyms in daily clinical work. 
Neoplasia describes the state of neoplasm growth. The type of proliferation in neoplasia is 
called neoplastic proliferation, as the cells do not die as they should and divide more quickly, 
forming tissue without normal function. In contrast to this term, non-neoplastic proliferation 
is more common in response to inflammation, tissue damage and repair, etc. It is usually 
occurring according to a physiological requirement and the formed tissue is mature and 
functional. This kind of proliferation is under control and will be stopped when the initial 
factor is removed. The proliferating cells are a polyclonal population, which comes from 
different parental cells. Compared to non-neoplastic proliferation, neoplastic proliferation has 
several unique characteristics: 1. Neoplastic proliferation is not coordinated with the body, 
and is harmful to the body. 2. Neoplastic proliferation is monoclonal. A cell population 
originates from one neoplastic transformed parental cell, which is a phenomenon called 
neoplasia clonality. 3. In neoplastic proliferation, the cell morphology, metabolism, function, 
and differentiation are abnormal. 4. In neoplastic proliferation, the cells have relative 
autonomy. The growth is rapid and out of control. Even if the initial factors have been 
removed, the proliferation effect cannot be eliminated, because of the gain-of-function 
oncogenes and/or the loss-of-function tumor suppressor genes, which can be passed on to the 
offspring cells. 
There are benign and malignant neoplasms. Benign neoplasms usually grow slower and have 
no capability to invade into the surrounding tissues or metastasize to other parts of the body. 
Benign neoplasms are usually not fatal unless vital organs are pressed, such as brainstem 
compression. In contrast, malignant neoplasms grow faster and have the capability to invade 
the surrounding tissues and to metastasize to distant organs. Metastasis is the main course of 
death from malignant neoplasms. Actually, benign and malignant neoplasms are not totally 
black and white, and sometimes there is a grey zone in between. Pre-malignant neoplasms, 
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which are non-invasive, have the potential to become malignant neoplasms. In clinic, pre-
malignant neoplasms are difficult to diagnose and/or to design treatment strategies against.  
The malignant neoplasms, also known as cancers, can be divided into different groups, e.g. 
carcinoma, sarcoma, melanoma, lymphoma, leukemia. Carcinomas are the most commonly 
diagnosed cancers. They are originated from epithelial cells in breasts, lungs, pancreases, and 
other organs. 
1.2 BREAST CANCER 
1.2.1 Epidemiology 
Breast cancer is one of the most common cancers and the second most common cause of 
cancer death in women worldwide [1]. Several risk factors of breast cancer have been 
discovered (Table 1) [2-4]. 
Table 1. Established and probable risk factor for breast cancer  
Factor High-risk group 
Age Age ≥ 55-year-old 
Race White 
Geographical location Developed country 
Age at menarche Menarche before age 11 
Age at menopause Menopause after age 45 
Age at first full pregnancy Age of first childbirth ≥ 40-year-old 
Family history Breast cancer in the first-degree relative when young 
Previous benign disease Atypical hyperplasia 
Mammographic density Density ≥ 75% of the mammogram 
Cancer in another breast  
Socioeconomic group Group I and II 
Lifestyle  
        Diet High intake of saturated fat 
        Body weight Body mass index >35 
        Alcohol consumption Excessive intake 
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        Smoking Initiate smoking before first birth 
Exposure to ionizing radiation Abnormal exposure in young female after age 10 
Taking exogenous hormones  
        Oral contraceptives Current use 
        Hormone replacement therapy Use for ≥ 10 years 
        Diethylstilbestrol Use during pregnancy 
1.2.2 Pathophysiology 
Breast cancers are usually originated from epithelial cells of mammary glands. The 
carcinogenesis of breast cancer could be due to different molecular events, such as DNA 
damage and genetic mutations. Each molecular abnormality may lead to the distinct genomic 
profiling and a different breast cancer subtype.  Some individuals with a family history of 
breast and/or ovarian cancer inherit defects in DNA, such as mutations in BRCA1/2, TP53, or 
PTEN. An abnormal estrogen exposure can also lead to mutations, which may contributes to 
the breast cancer formation [5]. Besides the genetic events, the deficiency of immune system 
also contributes to the development of breast cancer. High activity of proliferation signaling 
and/or low activity of cell cycle inhibition signaling may affect several cancer cell behaviors, 
such as cell proliferation, cell survival, cell apoptosis, cell adhesion, and cell motion. 
1.2.3 Breast cancer categories 
1.2.3.1 Grade 
Breast cancer grade indicates the differentiation level. According to tubule formation, nuclear 
pleomorphism and mitotic count, breast cancer can be classified as low-grade (well 
differentiated), intermediate-grade (moderately differentiated), and high-grade (poorly 
differentiated). Lower-grade tumors usually have a better survival rate and can be treated less 
aggressively; while higher-grade tumors usually link with worse survival rate and require 
more aggressive medications. 
1.2.3.2 Stage 
Breast cancer stage indicates the overall distribution of the cancer cells in the whole body, 
which is mostly referenced to make the therapeutic decisions. The TNM staging is the most 
commonly recommended, and is based on the size of the tumor (T), lymph node involvement 
(N), and whether the cancer has metastases (M) to obtain the overall stage. Breast cancer 
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stage scales from 0 to IV, spanning from noninvasive breast cancer, early invasive cancer to 
locally advanced breast cancer and metastatic breast cancer. The 5-year overall survival 
decreases from 99% in stage 0 to 24% in stage IV [6].  
1.2.3.3 Histopathological classification 
Histopathology classification is based on light microscopy observation of biopsy specimen. 
Most breast cancers are carcinomas. Carcinoma is a type of cancer originating from epithelial 
cells. Adenocarcinoma is the most common pathological subtype in breast cancers, which 
refers to a carcinoma featuring glandular-related tissue cytology and gland-related molecular 
products. The three most common histopathological types stand for three-quarters of breast 
cancers: Invasive (or infiltrating) ductal carcinoma (IDC) (55%), Ductal carcinoma in situ 
(DCIS) (13%), and Invasive (or infiltrating) lobular carcinoma (ILC) (5%) [7]. DCIS, also 
called intraductal carcinoma, is non-invasive, as the cells have not invaded through the basal 
layer of the ducts into the surrounding breast tissue. DCIS is a pre-cancer and up to 30% of 
DCIS cases will develop an invasive ductal carcinoma within 10 years after the DCIS 
diagnosis. An accurate way to predict the transformation from DCIS to invasive carcinoma is 
still missing. IDC is the most common type of breast cancer. It starts from a milk duct, breaks 
through the basal layer of the duct, and has the capability to metastasize through lymphatics 
and blood stream. ILC starts in the glands (lobules) of breast, and breaks through the basal 
layer of lobules. Also, like IDC, ILC can metastasize to other parts of the body. 
1.2.3.4 Clinical-pathological classification 
Breast cancer clinical-pathological classification is based on the expression of estrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER2) [8, 9]. Breast cancers are grouped as hormone receptor-positive (positive for estrogen 
receptor and progesterone receptor), HER2-positive, triple positive (positive for estrogen 
receptor, progesterone receptor, and HER2), and triple negative breast cancer (TNBC) 
(negative for estrogen receptor, progesterone receptor, and HER2). The adjuvant therapy 
strategies for different groups are diverse. Endocrine therapy is the priority treatment for 
hormone receptor-positive patients. Trastuzumab is the target treatment for HER2-positive 
patients. Moreover, triple-negative breast cancer (TNBC) patients mainly use chemotherapy 
and radiotherapy.  
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1.2.3.5 Molecular subtype 
Genome-wide microarray analysis has been used to classify invasive breast cancer into 
different groups: Luminal A, Luminal B, normal-like, HER2 type, and basal-like (Table 2) 
[10-12]. There are also some breast cancers that do not fall into any of these groups, and they 
can be listed as unclassified. Most of the breast cancers belong to the luminal groups. 
Luminal A tumors tend to be tumor grade 1 or 2. Among all these groups, luminal A has the 
best prognosis [13]. The women in the luminal B group are usually diagnosed in an earlier 
age than in the luminal A group [14]. The luminal B group patients have a poorer prognosis 
than the luminal A group, because they tend to have worse tumor grade, larger tumor size, 
and more lymph node-metastasis [13, 15, 16]. The HER2 type is not equal to HER2 positive 
breast cancer. The HER2 type tends to be lymph node-positive and high tumor grade. The 
prognosis of the HER2 type breast cancer is usually worse than any luminal type. Women 
with HER2 type tumors are often diagnosed at younger ages than those with luminal A or 
luminal B tumors. Most of the basal-like breast cancers and triple negative breast cancers 
(TNBC) overlap. However, there are still some basal-like tumors not belonging to TNBC; 
and also, some TNBC not belonging to the basal-like group. Most of the BRCA1 mutation 
associated breast cancers are both basal-like and TNBC [17]. The basal-like tumors tend to be 
very aggressive and usually have a poor prognosis. Normal-like tumors tend to be small and 
have a good prognosis. There is a dispute about whether normal-like tumors constitute a 
specific molecular subtype, or if they are just a group of unclassified tumors.   
Table 2. Molecular subtypes of breast cancer  
Molecular subtypes Molecular markers Prevalence 
Luminal A ER+ and/or PR+, HER2-, low Ki67 40% 
Luminal B ER+ and/or PR+, HER2+ (or HER2- with high Ki67) 20% 
HER2 type ER-, PR-, HER2+ 10-15% 
Basel-like ER-, PR-, HER2-,  
cytokeratin 5/6+ and/or EGFR+ 
Overexpression of CK15, CK17, vimentin and c-kit  
15-20% 
 12 
Normal-like ER-, PR-, HER2-, cytokeratin 5/6- and EGFR- 
Expression of CK8/18 
10% 
1.2.4 Current treatments and therapeutic challenges 
Through a century change, the greatest progress of breast cancer treatment has been seen: the 
revolution of locoregional surgery; the application of adjuvant chemotherapy; the therapeutic 
exploration of estrogen receptor; the targeting of the human epidermal growth factor receptor 
complex; the use of neoadjuvant treatment; and the approaches of biology-driven systemic 
therapies. Surgery usually is the primary therapy for breast cancer. Adjuvant therapy is given 
after primary therapy to increase the disease-free survival. Neoadjuvant therapy is given 
before primary therapy, to shrink the tumor for surgery [18]. Neoadjuvant therapy is given in 
the same manner as adjuvant therapy, including chemotherapy, endocrine therapy, radiation 
therapy, target therapy (e.g. Trastuzumab), or a combination treatment. A commonly used 
drug in endocrine therapy is tamoxifen, which blocks estrogen receptor activity. ER positive 
patients benefit  from tamoxifen treatment, however, many patients develop tamoxifen 
resistance over time. Endocrine therapy resistance is a major challenge in the clinic. Loss of 
ER expression cannot explain all of the resistance. It is urgent for scientists to characterize the 
resistance mechanisms. Based on such scientific studies, this challenge may be conquered. 
1.3 P21-ACTIVATED KINASE 4 
1.3.1 Small GTPases and the p21-activated kinase family 
The Ras superfamily consists of various families of small GTPases. Small GTPases are a type 
of monomeric GTP-binding proteins, which are homologous to the alpha subunit of 
heterotrimeric G-proteins, and usually in the range of 20-25 kDa. They function as hydrolase 
enzymes to hydrolyze guanosine triphosphate (GTP). They are "molecular switches" – active 
when GTP is bound and inactive when GDP is bound. Three classical regulators of GTPases 
are GEFs (guanine nucleotide exchange factors), GAPs (GTPase-activating proteins), and 
GDIs (guanine nucleotide dissociation inhibitors). Based on structure, sequence and function 
similarity, the Ras superfamily can be divided into five main families: Ras (mainly for cell 
proliferation), Rho (mainly for cell morphology), Ran (mainly for nuclear transport), Rab 
(mainly for vesicle transport), and Arf (mainly for vesicle transport) family GTPases. Among 
them, only the Ras and Rho families transmit signals from cell-surface receptors. The Rho 
family GTPases regulate many aspects of cell morphology. There are three heavily studied 
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members of this family: Rac1 (mainly affects lamellipodia), Cdc42 (mainly affects filopodia), 
and RhoA (mainly affects stress fibers). The main effectors of these GTPase are PAK, ACK, 
MLK, MRCK, and ROCK. 
The p21-activated kinase (PAK) family is among the most extensively studied effectors of 
Rac1 and Cdc42. The PAK family consists of six members and can be divided into two 
groups based on sequence homology: PAK1-3 in group I and PAK4-6 in group II. PAKs are 
involved in many cellular functions, such as cell proliferation, cell migration, cell survival 
and cell death [19]. Moreover, they also play critical roles in tumor progression, such as 
oncogenic transformation, metastasis and angiogenesis [19]. PAKs, especially PAK1 and 
PAK4, have often been found overexpressed and/or hyperactivated in many different human 
cancer forms, such as breast cancer, ovarian cancer, colon cancer and prostate cancer [19]. 
Among them, breast cancer is the most extensively studied cancer for PAKs. Dominant 
negative PAK1 leads to a significant reduction of the size of MDA-MB-631 xenograft tumors 
in mice. Interestingly, the transgenic mice with constitutively active PAK1 develop 
mammary tumors [20]. These results indicate an essential role of PAK1 in breast cancer. 
PAKs regulate several cell signaling pathways controlling cancer cell proliferation, survival, 
invasion, metastasis, angiogenesis, epithelial-mesenchymal transition, and metabolism. First, 
for cell proliferation, several PAK members positively regulate key cell cycle signaling 
pathways such as ERK, AKT and WNT in many cancer cell types. In the ERK pathway, 
PAK1 can phosphorylate c-RAF at S338 and MEK1 at S298 [21]. In a kinase-independent 
manner, PAK1 scaffold function may also contribute, as the over-expression of kinase-dead 
PAK1 can activate ERK in the absence of c-RAF S338 phosphorylation [22]. Moreover, 
PAK1 scaffold function can also facilitate Akt stimulation by PDK1 and contribute 
recruitment of Akt to the membrane [23]. The phosphorylation of -catenin by PAK1 at S663 
and S675 stabilizes -catenin and promotes its nuclear localization, which subsequently 
upregulates its transcriptional activity [24]. PAK4 was shown to have the similar role [25]. 
Second, several PAK members have been shown to phosphorylate BAD directly or indirectly 
indicating a regulatory role in apoptosis [26, 27]. Third, both PAK1 and PAK4 can 
phosphorylate LIM kinase, which subsequently phosphorylates Cofilin, resulting in 
polymerization of actin filaments thereby promoting cell motility [28, 29].  
1.3.2 PAK4 structure and function 
PAK4 is the most extensively studied group II PAK. PAK4	was	firstly	identified	as	an	
effector	of	Cdc42	to	induce	actin	polymerization	and	the	formation	of	filopodia	[30].	
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Like	other	PAKs,	PAK4	consists	of	a	conserved	C‐terminal	serine/threonine‐kinase	
domain	and	an	N‐terminal	regulatory	domain.	Unlike	the	auto‐inhibition	of	group	I	
PAKs,	the	group	II	PAKs	are	constitutively	phosphorylated.	However,	a	recent	study	
found	an	autoinhibitory	pseudosubstrate	in	the	PAK4	N‐terminal	region	(Figure	1)	[31,	
32].	In	the	resulting	new	model	of	PAK4	regulation,	the	binding	of	an	SH3	domain	to	the	
newly	defined	autoinhibitory	pseudosubstrate	leads	to	the	promotion	of	PAK4	kinase	
activity	[33].	
 
 
Figure 1. PAK4 protein domain structure.  
Besides the Lim kinase, BAD and -catenin mentioned above, additional PAK4 substrates 
have been identified, and some of them are shared with other PAKs. For example, PAK4 
phosphorylates GEF-H1, consequently reducing RhoA activity [34]. GEF-H1 is also the 
substrate of PAK1 and PAK2 [35, 36]. Moreover, PAK4 can regulate cell migration by 
phosphorylating integrin 5 [37].  
PAK4 is highly expressed during development [38]. Although the PAK4 expression is 
universal, it only has relatively high expression levels in limited adult organs, such as prostate, 
testis, and colon, and in most of the other adult tissues the expression levels are quite low [30]. 
Moreover, PAK4 may be involved in cancer progression [39]. For example, PAK4 may play 
a role in cell transformation, since a constitutively active PAK4 mutant transforms mouse 
embryonic fibroblasts NIH3T3 cells in vitro; dominant-negative PAK4 partially inhibits Ras-
induced transformation in NIH3T3 cells [40, 41]; and overexpression of PAK4 makes 
NIH3T3 cells tumorigenic in athymic mice [42]. PAK4 may also be required for anchorage-
independent growth of HCT116 human colon carcinoma cells [40, 41]. Moreover, by 
phosphorylating BAD, PAK4 can also protect HeLa cells from apoptosis [43]. Importantly, 
PAK4 is up-regulated in most human cancer cell lines [41], and has also been found 
overexpressed in several human cancer forms, including breast cancer, colon, esophageal, 
pancreas, and ovarian cancer [42, 44-46]. High PAK4 expression in ovary cancer is linked to 
poor patient survival and chemotherapy resistance [45]. In breast cancer cells, PAK4 inhibits 
cell adhesion [40, 47, 48] and promotes cell migration by inducing αvβ5 mediated breast 
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cancer cell motility [29, 37, 48-50]. However, the potential role of PAK4 in breast cancer 
remains largely elusive. 
1.4 RING-FINGER PROTEIN 31 
1.4.1 Ubiquitination 
Ubiquitin is a 76-amino-acid polypeptide (8kDa) that can be covalently conjugated to other 
substrate proteins through a process called ubiquitination. The attachment of ubiquitin to 
substrates requires three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-
conjugating enzyme), and E3 (ubiquitin ligase). As the initial step of ubiquitination, E1 uses 
ATP hydrolysis energy to attach and activate ubiquitin; then passes this activated ubiquitin to 
E2. E3 provides platforms for binding of E2 and a selected substrate protein; E3 thereby 
transfer ubiquitin to the specific substrate. This process may repeat several times to form 
different types of ubiquitin chains (poly-ubiquitination), and some ubiquitinated proteins can 
be targeted by the 26S proteasome for degradation [51]. Protein modification with one single 
ubiquitin is called mono-ubiquitination, and can be a start of a poly-ubiquitination or a 
separate event [52]. Ubiquitination can be reversed by deubiquitinating enzymes (DUBs) to 
remove ubiquitin from the substrates. 
Humans have approximately 500-1000 different E3 ligases, which can be divided into four 
families according to the functional domains: HECT, RING-finger, U-box and PHD-finger 
[53]. Among them, the RING-finger E3 ligase family is the largest. The two most well-
known examples in the RING-finger E3 ligase family that have been associated with 
carcinogenesis are Murine double minute clone 2 (Mdm2) and BRCA1. The human 
homologue of Mdm2 is also called Hdm2. Mdm2 is found overexpressed in many human 
cancers. Mdm2 interacts and targets p53 for degradation. Mdm2 has functions in protein 
ubiquitination, DNA double strain break repair, and gene expression regulation. BRCA1 is a 
tumor suppressor. BRCA1 mutations are found in around 70% of all familial breast or 
ovarian cancers [54].  
RING-In-Between-RING (RBR) E3 ligase is a subfamily of the RING-finger E3 ligase 
family. RBR is defined by an RING1-in-between-ring (IBR)-RING2 motif. The RBR family 
has functions in NF-kB signaling and nuclear receptor (NR) signaling. Some of the RBR 
family members are critical in human diseases, such as Parkin in Parkinson’s disease, Dolfin 
in familial amyotrophic lateral sclerosis and ARA54 in prostate cancer. 
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1.4.2 RNF31 structure and function 
RING-finger protein 31 (RNF31), also called HOIL-1-interacting protein (HOIP), is encoded 
by the RNF31 gene that was first cloned in 2004 [55]. It belongs to the RBR family. Figure 2 
shows the RNF31 protein domain structure [56]. The PUB domain binds to cofactors. The 
ZNF_RBZ domain is related to the ubiquitin binding function. The UBA domain can bind 
RBCK1 and mediates linear ubiquitination of IKK. The RING-IBR-RING domain is the 
main functional domain in an ubiquitin ligase. 
 
 
Figure 2. RNF31 protein domain structure. PUB: putative ubiquitin binding domain; ZNF_RBZ: Zinc finger 
domain in Ran-binding proteins domain; UBA: ubiquitin binding associated domain. 
 
RNF31 is highly expressed in muscle, heart, and testis [56]. RNF31 was originally identified 
as a muscle-specific tyrosine kinase receptor interacting protein [57]. RNF31 knockout in 
mice leads to embryonic lethality. In cancer-related studies, RNF31 has been reported to 
cause cisplatin resistance through ERK and JNK pathways. Moreover, RNF31 can form the 
linear ubiquitin assembly complex (LUBAC) together with RBCK1 and SHARPIN. This 
LUBAC can facilitate linear ubiquitination of IKK [58].  
1.5 ESTROGEN RECEPTOR ALPHA 
1.5.1 Estrogen receptor alpha signaling 
Estrogen receptor (ER) is a member of the nuclear receptor (NR) superfamily. ER has two 
main forms, ER and ERwhich are encoded by the ESR1 and ESR2 genes, respectively. 
ERwas firstly reported in the 1960’s and cloned from MCF-7 cells in 1985 [59, 60]. ER 
was cloned in 1996 [61], which will not be discussed in detail here.  
ER protein has 595 amino acids, which consist of four main functional domains: a DNA-
binding domain (DBD), a ligand-binding domain (LBD) and two transcriptional activation 
functions (AF-1 and AF-2) (Figure 3). 
 
Figure 3. ER protein domain structure. A-F: (A/B) N-terminal regulatory domain: contains the activation 
function 1 (AF-1), which is hormone-independent. (C) DNA-binding domain (DBD): binds to DNA estrogen 
response elements. (D) Hinge region: contains nuclear localization sequences and interacts with AP-1. (E) 
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Ligand binding domain (LBD): contains the activation function 2 (AF-2), which is hormone-dependent. (F) C-
terminal domain: the function is not clear.  
ER is activated by estrogen (17-estradiol, E2). Upon estrogen binding, the ER protein 
can shuttle from cytoplasm into the nucleus to form dimers, which subsequently bind to 
estrogen response elements in the DNA and active downstream target genes [62].  
1.5.2 ER in breast cancer 
Around 70% of breast cancers are ERpositive. The risk of breast cancer is higher in breast 
tissues with high ER expression [63]. Given that ER is the target gene of itself, ERcan 
exert a positive self-regulation. Moreover, high levels of ERexpression in breast cancer 
cells can lead to increased E2-independent activity of ER [64]. ERpositive cancers tend to 
depend on ERsignaling for cell growth, which makes ERa suitable target for breast 
cancer therapy. 
For ERpositive breast cancer patients, selective estrogen receptor modulators (SERMs) are 
standard endocrine treatment. The most common used drug in SERMs is tamoxifen. 
Tamoxifen shares a similar structure with E2, and acts as a competitive inhibitor of E2 
binding to ER. Unlike SERMs, which can be used for all ages of breast cancer patients, 
aromatase inhibitors are only used for post-menopausal patients [65]. By suppressing 
aromatase enzyme activity, aromatase inhibitors block the estrogen production from 
androgens. In pre-menopausal women, ovarian aromatase is responsible for estrogen 
synthesis; while in post-menopausal women, aromatase in fat and muscle mainly function to 
produce circulating estrogen [66]. In the hypothalamic/pituitary feedback loop in pre-
menopausal women, lower estrogen levels lead to an up-regulation of aromatase enzymes in 
the ovary. Therefore, aromatase inhibitors are ineffective in pre-menopausal patients.  
The largest challenge of tamoxifen treatment is drug resistance. There are many mechanisms 
that may contribute to tamoxifen resistance. However, the mechanisms of tamoxifen 
resistance are not entirely clear. It is known that either loss of ERα function or upregulation 
of ERα function (or loss of control) can lead to tamoxifen resistance. Tamoxifen resistance 
has been linked to high expression of ER co-activators, such as SRC, which can promote 
ER transactivaty and cell proliferation [67]. Moreover, tamoxifen resistance may also occur 
due to the cells shifting to depend on other pathways for cell proliferation, such as HER2, 
EGFR, and NFB pathways. In this case, blocking of ERα pathway is not efficient. ER 
post-translational modifications also have functions in tamoxifen resistance, such as 
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phosphorylation. Multiple phosphorylation sites in ER have been discovered by mass 
spectrometry on phosphopeptides. Some of them have been detected in breast tumor biopsy 
samples, such as S118 [68-74], S167 [74, 75], S282 [76, 77], S305 [77], and T311 [76]. 
There are some phosphorylation sites linked to tamoxifen resistance, such as S104/S106, 
S167, and S305 [78]. Among these, S305 is the only phosphorylation site that has displayed 
clinical correlation with tamoxifen resistance. ER-S305phosphorylation positive breast 
cancer patients tend to be resistant to adjuvant tamoxifen treatment, while ER-S305 
phosphorylation negative breast cancers have been linked to a better recurrence-free survival 
with tamoxifen treatment [79, 80]. Consequently, blocking ER-S305 phosphorylation may 
become a new therapy strategy. 
1.6 P53 
The p53 protein was firstly reported in 1979 [81]. TP53, the human gene that encodes p53, 
was uncovered in 1984 [82]. p53 was initially believed to be an oncogene, because p53 levels 
were higher in many tumors compared to normal tissue, and higher in transformed cell lines 
compare to non-transformed [83, 84]. Until the second half of the 1980s, p53 was amended as 
a tumor suppressor gene, because it was found inactivated in human cancers and loss of p53 
promoted cancer [85, 86]. The history of p53 research over the past 30 years proves that p53 
is one of the most extensively studied genes and proteins in the cancer area. 
Human p53 protein consists of 393 amino acids and can be divided into three fragments (N-
terminal, central core, C-terminal), and each of them corresponding to specific functions 
(Figure 4) [87]. The N-terminal fragment contains the transactivation domain (binds to 
transcription factors) and a Src homology 3-like (SH3) domain (interacts with SIN3). SIN3 
can protect p53 from degradation. The central core is the DNA-binding domain. The C-
terminal contains nuclear localization and export signals (NLS and NES), a regulatory 
domain and the tetramerization domain.
 
Figure 4. P53 protein domain structure. TAD: Transactivation domain; SH3: Src homology 3-like domain; 
NLS: Nuclear localization signal; TET: Tetramerization domain; NES: Nuclear export signal; REG: Regulatory 
domain. 
The regulation of p53 is tightly controlled through several mechanisms, such as 
transcriptional modifications, translational modifications, post-translational modifications, 
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and subcellular localization. In unstressed cells, p53 has a short half-life with continuous 
ubiquitylation and subsequent 26S proteasome degradation. The ubiquitylation is mainly due 
to the interaction of p53 with MDM2 [88]. This interaction can be disrupted in the cells in 
situations like DNA damage, oxidative stress, or oncogene activation. When p53 
ubiquitylation is suppressed and its half-life thereby increased, the stabilized p53 protein 
accumulates in the nucleus to form homotetrameric complexes and works as a transcriptional 
regulator. P53 initiates cellular response through transcriptional modifications of distinct 
target genes that primarily function to prevent the proliferation of damaged cells. Although 
P53 is mainly a nuclear protein, p53 also has functions in the cytosol by protein-protein 
interactions. p53 can translocate to the mitochondria, where it interacts with anti-apoptotic 
proteins (e.g. BCL2 and BCL/XL) to induce cell apoptosis [89]. 
The importance of p53 in cancer is illustrated by the fact that p53 is one of the most 
frequently mutated tumor suppressor genes in most of the human cancers [90]. Mutant p53 
may lose functions by several different mechanisms. Compared with wild-type p53, mutant 
p53 proteins generally increase the intensity of phosphorylation and acetylation at the sites, 
which contribute to the stabilization effect, and subsequently facilitate accumulation of 
dysfunctional mutant p53 in the nucleus [87]. In the nucleus, the mutant p53 can form 
tetrameric complexes together with wild-type p53 and hamper the functions of wild-type p53. 
In addition to abolishing the tumor suppressor function of wild-type p53, mutant p53 often 
act as an oncogene with new activities, termed “gain-of-function”, that can contribute to 
apoptosis resistance, genomic instability, aberrant cell cycle, invasion, and inflammation [91, 
92].  
As in other cancers, p53 plays important roles in breast cancer. Approximately 31% of breast 
cancer patients carries p53 mutations [93]. In Luminal A, Luminal B, HER2 type, and basal-
like breast cancers, the percentage of mutant p53 contains are 15%, 30%, 75%, and 80%, 
respectively [16]. This illustrates that breast cancers with lower ER and worse prognosis 
tend to more frequently carry p53 mutations.  
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2 AIMS 
The general aim of this thesis is to contribute to the knowledge of breast cancer. The specific 
aims for each paper are described as following: 
I. To elucidate the role of RNF31 in ER signaling in breast cancer. 
II. To identify the role of RNF31 in p53 signaling in breast cancer. 
III. To determine the role of PAK4 in ER signaling in breast cancer. 
IV. To investigate the role of PAK4 in mouse mammary gland development and 
mammary tumor progression. 
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3 MATERIALS AND METHODS 
Breast cancer is a group of diseases that have different pathology patterns, genomic features, 
and outcomes. No single model could mimic all aspects of breast cancer. However, it is still 
necessary to develop new models to contribute to our understanding and therapeutic targeting 
of breast cancer. There are different breast cancer models, such as cell lines, xenografts and 
genetically engineered animals. In this section, the advantages and disadvantages of these 
breast cancer models will be discussed, although some of them were not used in the studies of 
this thesis. 
3.1 CELLS 
Cells are the most commonly used models for breast cancer studies, because there are 
relatively economical, and easily to propagate and culture. For breast cancer research, the 
commonly used cells are cell lines and primary cells. There are many differences between 
human breast cancer cell lines and patient primary breast cancer cells [94, 95], such as 
genomic alterations, suggesting that during the establishment or after a period of growth and 
several passages, cell characteristics can change and may become quite different from 
the initial cells. Unlike primary cells, which are usually isolated from primary tumor lesions, 
most cancer cell lines are isolated from metastasized cells, which are more aggressive. 
Noteworthy, most cell culture were performed on traditional two-dimensional (2D) plastic. 
Compared to 2D culture, three-dimensional (3D) cultures are much better for dynamic 
interactions between cells and extracellular matrix (ECM) [96]. The ECM has also been 
shown to be an important regulator of cancer cell morphology and behavior [97]. Moreover, 
normal cell culture is homotypic and lacks many features of tissues, such as blood vessel, and 
other cell types communication, which is remarkably different from the breast cancer 
microenvironment. Heterotypic cultures, which culture the tumor cells together with stromal 
cells, allow more focus on tumor-stromal cells interaction, such as fibroblasts and 
macrophages. 
3.2 XENOGRAFTS 
Many cancer cell lines can be cultured as xenografts, which allow us to analyze the tumor 
formation, progression and metastasis in a lifelike biological system. However, the xenografts 
are usually performed in immunocompromised mice, with defect immune systems, which are 
important in tumor pathophysiology. Moreover, for xenografts, cells are usually 
subcutaneous injected into the flank of the mouse, which is different from mammary gland 
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microenvironment. In comparison, orthotopic transplantation into the mammary fat pad is 
more favorable. Also, from non-invasion to invasion tumors, the cancer cells break through 
the basement membrane. However, the xenograft tumors do not have this histological 
structure and do not have the restriction of the basement membrane. For metastasis, the 
xenografts metastasis mostly occur in the lung; while in human, breast cancer can metastasize 
to the lung, lymph nodes, bone, liver, and brain.  
Clinical isolates can also grow as xenografts, which is a preclinical model and a distinct way 
to expand patient-derived breast cancer tissue [98]. However, because of the difficulty of 
clinical samples access, the uncertain transplantation efficiency, and the treatment predicting 
limitation, this technology has not yet been commonly adopted. 
3.3 GENETICALLY ENGINEERED MICE 
Among genetically engineered breast cancer research models, genetically engineered mouse 
(GEM) is the most common used model. Genetic modifications in breast cancer GEM models 
include the loss of tumor suppressor genes (such as Trp53, Brca1, or Pten) or gain of 
oncogenes (such as Erbb2, Myc, or PyMT). For the tissue specificity of oncogene targeting, 
special promoters are used, such as mouse mammary tumor virus long terminal repeat 
(MMTV-LTR), whey acidic protein (WAP), metallothionin (MT), and cytokeratin 14. 
Ideally, these promoters should be mammary-specific, but most of them are also expressed in 
other tissues [99]. Another negative aspect of many of these models is that some promoters, 
like MMTV and WAP, are hormonally regulated. The expression of these promoters 
increases during pregnancy and peaks at lactation which may affect tumor etiology [100]. 
Because most of the breast cancers originate in the mammary gland epithelial cells, the 
MMTV promoter, which is mainly expressed in mammary gland epithelial cells, is widely 
used in breast cancer GEM models [101]. This is also the reason why this promoter is used in 
paper IV study. Advanced genetic modification strategies are used in conditional and 
inducible GEM, such as Cre/loxP recombinase-mediated gene deletion GEM and tetracycline 
(Tet)-regulatable transgenes (Tet-Off and Tet-On) GEM. Comparing breast cancer mouse 
models with human breast cancers, both of them have similar breast cancer oncogenes, 
multiple genetic mutations, and analogous tumor pathological progression. For sure they also 
have many differences. Similar with the xenografts, metastasis of breast cancer GEM is also 
more commonly occurring in the lung; while in human, breast cancer can metastasize to the 
lung, lymph nodes, bone, liver, and brain. Moreover, mouse mammary tumors have less 
fibrosis and inflammation as compared to human breast cancers. It is also worth mentioning 
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that because of the diversity of human breast cancers, no individual GEM can represent this 
disease perfectly. 
In paper IV study of this thesis, we used one of the most extensively studied breast cancer 
GEM, MMTV-Polyoma virus middle T antigen (MMTV-PyMT), since it shares many 
properties with human breast tumors. For example, during tumor progression, there is a 
gradual loss of steroid hormone receptors; and the tumor progression stages (hyperplasia, 
adenoma, early and late carcinoma) are similar to human breast cancers [102]. Moreover, this 
mouse model has short latency, high penetrance and a metastatic potential independent of 
pregnancy. One obvious drawbacks of this model is that PyMT is not expressed in human 
breast cancer. However, several critical pathways contributing to carcinogenesis in MMTV-
PyMT mice are also altered in human breast cancers. The deletion of c-Src results in a 
significant inhibition of PyMT tumor initiation, which shows the essential role of the Src 
kinase in the PyMT mouse model [103]. Another kinase that plays a critical role is focal 
adhesion kinase (FAK); it has been shown that specific depletion of FAK can reduce tumor 
metastasis in PyMT mice [104]. The evidence for the importance of TGF is that blockade of 
TGF inhibits mammary tumor metastasis in PyMT mice [105]. Besides the signal pathway 
analysis, gene expression profiling has indicated that the tumor generated in MMTV-PyMT 
mice shares features with the luminal subtype of human breast cancer [106].  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates 
estrogen-stimulated breast cancer cell proliferation 
Estrogen receptor  (ER) is a clinically important mediator of proliferation in ER positive 
breast cancer. Therefore, insight into the molecular mechanisms that control ER expression 
and stability are of outmost importance for the understanding of breast cancer. 
Upon knocking-down of RNF31 in MCF-7 cells, cell proliferation decreased dramatically in 
an E2-dependent manner, which mimicked ER depletion. Further experiments showed that 
the depletion of RNF31 reduced ER protein levels, activity and target gene expression 
levels. This means that RNF31 contributes to ER pathways. 
In patient specimen, RNF31 was expressed at higher levels in breast tumors compared to 
adjacent breast tissues. Both in RNF31-depletion microarray data of MCF-7 cells and in the 
TCGA breast cancer patient database, the expression of RNF31 was correlated with ER-
regulated genes. 
Further, RNF31 was found to interact with ERα via the RBR domain and facilitate ERα 
mono-ubiquitination. Immunofluorescence staining showed that the interaction occurred 
mainly in the cytosol. 
In previous studies, RNF31 was shown to form the linear ubiquitin assembly complex 
(LUBAC) together with RBCK1 and SHARPIN. LUBAC conjugated linear poly-ubiquitin 
chains to substrates such as IKK, which subsequently facilitates NFB pathway signaling. 
Here, we have presented another type of ubiquitin induced by RNF31, which is the mono-
ubiquitination on ER(Figure 5). 
There is a large medical need to derive novel therapeutic strategies and targets for breast 
cancer including novel strategies that modulate estrogen signaling. In this study, we identified 
such a novel mediator of estrogen signaling that we believe it should be further explored for 
its potential as a target in breast cancer. This study identified for the first time the E3 
ubiquitin ligase RNF31 as a modulator of ER signaling in human breast cancer cells by a 
non-transcriptional mechanism, correlating with association and mono-ubiquitination of ER 
and enhanced ER protein stability. Importantly, RNF31 depletion caused the inhibition of 
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estrogen-dependent cell proliferation, suggesting inhibition of RNF31 as a potential 
therapeutic strategy in breast cancer.  
 
Figure 5. Hypothetical model for the functional interplay of RNF31 with ER signaling in breast cancer 
cells. 
4.2 PAPER II 
RING finger protein 31 promotes p53 degradation in breast cancer cells 
P53 is an important tumor suppressor protein. Wild type p53 function often correlates with 
good chemotherapy response and good prognosis in cancers. Therefore, insights into the 
molecular mechanisms that control p53 levels are important for the improvement of breast 
cancer therapeutics. In this study, we identified such a novel mediator of p53 signaling, which 
deserves further exploration for its potential as a target in breast cancer.  
In the microarray analysis performed in paper I, we found that knocking-down RNF31 in 
MCF-7 cells significantly upregulated many P53-activated genes. We then put this gene list 
into the TGCA clinical sample database and found that 50% of the genes also display a 
negative correlation in clinical data. These data showed that RNF31 might be a suppressor for 
P53 signaling. 
Further experiments showed that RNF31 knockdown in MCF-7 cells promotes p53 protein 
stability, p53 downstream target genes activity, and p53-dependent G1 cell cycle arrest.  
To analyze if RNF31 may function in cell death, we switched to the ZR751 cell line, which 
also express wild type p53, as MCF-7 cells don’t express caspase 3 and are resistant to 
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cisplatin. In cisplatin treatment, RNF31 depletion induced cell death in a p53-dependent 
manner.  
By depletion of RNF31 in MCF-7 cells, we observed a remarkable change of p53 protein 
levels without any change on p53 mRNA. This indicates that the regulation of p53 may be 
caused by a post-translational modification. Later experiments showed that RNF31 associated 
with the p53/MDM2 complex, and induced p53 poly-ubiquitination in MDM2-dependent 
manner.  
We then studied how RNF31 regulate p53 through MDM2. Through co-overexpression of 
RNF31 with MDM2 in HEK293 cells, we found that MDM2 was stabilized by RNF31. By 
an immunoprecipitation ubiquitin assay, we found that RNF31 could reduce MDM2 poly-
ubiquitination. This effect was also observed in MCF-7 cells.  
In summary, this study identified for the first time the E3 ubiquitin ligase RNF31 as a 
modulator of p53 signaling. p53 protein could be degraded by a few E3 ligases such as Pirh1, 
COP1 and P300, and in particular by MDM2. RNF31 protein interacted with the MDM2/p53 
complex (Figure 6). In this process, RNF31 stabilized MDM2 by prohibiting its poly-
ubiquitination. This amplified the MDM2 effect on p53 and facilitied p53 degradation. This 
is how RNF31 suppresses p53 pathways in breast cancer cell. Importantly, RNF31 depletion 
in breast cancer cells caused cell cycle arrest and induced apoptosis in a p53-dependent 
manner suggesting inhibition of RNF31 as a novel potential therapeutic strategy in breast 
cancer.  
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Figure 6. Hypothetical model for the functional interplay of RNF31 with p53 signaling in breast cancer 
cells. 
4.3 PAPER III 
P21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen 
receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells 
Resistance to endocrine therapy remains an important clinical issue in breast cancer 
treatment. This study describes a potential mechanism in tamoxifen resistance, and a potential 
marker for endocrine therapy response prediction.  
PAK4 expression levels were consistently correlated with poor tamoxifen response in both 
METABRIC and KMPLOT databases. According to this, we hypothesized that PAK4 might 
contribute to tamoxifen resistance. Then we tested this hypothesis in human breast cancer cell 
lines. In MCF-7 cells, PAK4 overexpression promoted tamoxifen resistance. Consistently, the 
exposure of tamoxifen-resistant MCF-7/LCC2 breast cancer cells to a group II PAK (PAK4, 
5, 6) inhibitor, GNE-2861, sensitized these cells to tamoxifen. This indicates that PAK4 may 
be involved in tamoxifen resistance. 
To explore how PAK4 may cause tamoxifen resistance in breast cancer cells, it is necessary 
to unravel the role of PAK4 in estrogen receptor alpha (ERα) signaling. Interestingly, PAK4 
depletion or GNE-2861treatment decreased ERα protein levels, ERα target gene expression 
levels and ERα regulated reporter gene activity in MCF-7 cells. PAK4 depletion or GNE-
2861treatment also decreased E2 stimulated cell proliferation in MCF-7 cells.  
Futher, ERα protein levels were decreased, but with no changes in ERα mRNA levels upon 
PAK4 depletion. We further found that PAK4 increased ERα stability. Using an in vitro 
protein phosphorylation assay, we found that PAK4 could phosphorylate ERα at Serine 305. 
Previous experimental and clinical data suggested that ERα Ser305 phosphorylation may 
contribute to tamoxifen resistance in breast cancer [79, 80, 107-110]. One possible 
mechanism is that an altered orientation between ERα and its coactivator SRC-1 elevates the 
ERα transcription activity in the presence of tamoxifen [107, 108]. Also, phosphorylation of 
ERα Ser305 by PAK1 could trigger a secondary phosphorylation on Ser118, which may also 
contribute to tamoxifen resistance [110]. 
Interestingly, we found a positive feed-forward loop between PAK4 and ERα (Figure 7). 
PAK4 is a novel ERα target gene, and PAK4 in turn stabilized ERα protein and activated 
ERα pathway signaling. The stabilization and PAK4-mediated activation of ERα-dependent 
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transcription seems to occur via PAK4-mediated phosphorylation of ERα-Ser305. These 
results suggest that PAK4 may offer a novel drug target for breast cancer patients with 
tamoxifen resistance, and GNE-2861 may act as a candidate. 
 
Figure 7. Hypothetical model for the functional interplay of PAK4 with ER signaling in breast cancer 
cells. 
4.4 PAPER IV 
Increased MMTV-PyMT mammary tumor latency by MMTV-Cre-driven conditional 
gene depletion of p21-activated kinase 4 
Given the increased PAK4 expression levels in breast cancer, it is important to elucidate the 
function of PAK4 in mammary cancer progression in vivo. However, the in vivo cancer-
related functional evidence is so far limited to xenograft models. In this study, transgenic 
mice have been used to study endogenous mammary tumor development. 
Before a transgenic model with PAK4 depletion can be utilized to study cancer, it is critical 
to assessing role of PAK4 in the development of the normal mammary gland. We first 
identified the levels of PAK4 gene expression in the mouse mammary glands. PAK4 mRNA 
is expressed at relatively low level in mammary glands from virgin to pregnancy, but 
increased during lactation. 
Because of the embryonic lethality upon complete PAK4 gene depletion in mice, we have 
setup a mouse model lacking PAK4 in the mammary epithelium (MMTV-Cre; PAK4fl/fl) 
using the Cre/loxP system. To test the efficiency of the PAK4 gene depletion in MMTV-Cre; 
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PAK4fl/fl mice, the PAK4 mRNA was isolated from lactation mice. MMTV-Cre; PAK4fl/fl 
mice displayed a strong reduction of PAK4 mRNA levels compared to the control mice.  
To observe the ductal growth in juvenile and in adult virgin mice as well as the development 
during pregnancy and lactation, we examined mammary gland whole mounts and 
hematoxylin and eosin (HE) stainings of the mouse mammary gland tissues. However, we did 
not find any difference in mammary gland development between control mice and PAK4 
conditional knockout mice. To study the function of the mamamry gland, progeny nursed by 
MMTV-Cre; PAK4fl/fl female were found to have the same weight as in the control group 
during weaning. As Cre is expressed from postnatal day 22 in MMTV-Cre line D mice [111, 
112], we conclude that loss of PAK4 from this stage does not cause defects in mammary 
gland development from juvenile to lactation. The analysis of mammary gland involution 
after lactation is in progress. 
In MMTV-PyMT mice, PAK4 was found highly expressed in tumors compared to the 
surrounding normal mammary tissue. To test if genetic depletion of PAK4 may affect 
mammary tumor development and progression, conditional depletion of PAK4 was 
introduced into transgenic MMTV-PyMT mice, in which the tumors are induced by the 
polyoma middle T oncoprotein (PyMT). PAK4 depletion efficiency was tested by 
immunoblot of the mouse samples. By tumor palpation, conditional depletion of PAK4 was 
found to be associated with increased tumor latency (P<0.01). Mouse mammary gland whole 
mount stainings also showed that MMTV-Cre; PAK4fl/fl; MMTV-PyMT mice have less 
lesions compared to the control mice at 12 weeks of age. These results indicate a role for 
PAK4 in early tumorigenesis. Previous studies have shown that PAK4 may contribute to cell 
transformation, because in NIH3T3 cells, constitutively actived PAK4 caused cell 
transformation, while dominant-negative PAK4 partially inhibited Ras-induced cell 
transformation [40, 41]. Moreover, recent findings by Costa et al in our laboratory indicated a 
role for PAK4 in cancer cells to stay out of cellular senescence, a process acting as a barrier 
in early cancer development.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
In paper I and II, we reported novel roles for RNF31 in breast cancer. RNF31 increased ER 
protein stability, ER signaling activity and estrogen-dependent cell proliferation in breast 
cancer cells. Importantly, we also observed a positive correlation of gene expression between 
RNF31 and ER downstream target genes in breast cancer patient databases. The possible 
mechanism involves mono-ubiquitination modification of RNF31 on the ER protein. 
Moreover, we extended our microarray data analysis to explore the negative regulation of 
RNF31 on p53 signaling. As an atypical E3 ubiquitin ligase, RNF31 increased MDM2 
protein stability, and consequently contributed to p53 protein poly-ubiquitination and 
degradation. A negative correlation in gene expression levels between RNF31 and p53 targets 
genes was observed in breast cancer patient databases. Functionally, RNF31 depletion 
increased cell cycle arrest effect and cisplatin-induced apoptosis in a p53-dependent manner 
in breast cancer cells. These studies together suggest that, RNF31 may constitute a potential 
therapeutic target for breast cancer.  
In paper III and IV, we focused on the role of PAK4 in breast cancer. PAK4 expression was 
shown to correlate with tamoxifen resistance in two breast cancer clinical databases and to 
functionally promote tamoxifen resistance in human breast cancer cell lines. Further 
experiments showed that PAK4 could phosphorylate ER at Ser305 thereby increasing ER 
protein stability and signaling activity. To study the in vivo function of PAK4 in breast 
cancer, we generated PAK4 mammary gland conditional knockout mice. While we did not 
find any effect of this PAK4 depletion in mammary gland development, the depletion of 
PAK4 caused the prolonged tumor latency in MMTV-PyMT mice. Together, this may 
indicate that also PAK4 may be a potential target for breast cancer therapy. 
In papers I and II, we showed that RNF31 facilitates ERα mono-ubiquitination and p53 poly-
ubiquitination. Other studies also showed that RNF31 can form the linear ubiquitin assembly 
complex (LUBAC) together with RBCK1 and SHARPIN, which facilitate signal transduction 
of the NFKB pathway. It would be very interesting to elucidate the roles of RNF31 for 
different substrates in a variety of ubiquitin modifications. 
In papers I and II, we found that RNF31 plays important roles in breast cancer cells in vitro. 
However, the knowledge of RNF31 function in breast cancer is still limited. There is a lack of 
in vivo RNF31 breast cancer studies. As RNF31 knockout in mice leads to embryonic 
lethality, RNF31 conditional knockout mice will be a suitable model to analyze the roles of 
RNF31 in mammary development and tumorigenesis. 
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In paper I, II and III, the roles of RNF31 and PAK4 were analyzed in ERpositive cell lines. 
Endocrine treatment is specific for ERpositive breast cancer patients, while Trastuzumab 
is the target treatment for HER2-positive patients. However, there is at present no specific 
targeted treatment for triple negative breast cancer (TNBC). Also, it may therefore be 
interesting to examine the potential roles of RNF31 and PAK4 in triple negative breast cancer 
(TNBC).  
In paper III, ER was found to be a substrate of PAK4. Interestingly, ER is also a subtrate 
of PAK1. PAK1 and PAK4 are the most extensively studied members among the PAK group 
I and II, respectively. There is also other substrates shared between PAK1 and PAK4, such as 
Lim kinase, GEF-H1, BAD, Paxillin, Raf-1, and -catenin. It will be interesting to elucidate 
if there are more overlapping substrates between different PAK kinases. 
In paper III, a group II PAK inhibitor, GNE-2861, has been used. Inhibitors of both RNF31 
and PAK4 are under development. However, none of these has yet been successfully passed 
any clinical trial. One PAK4 inhibitor (PF-3758309, Pfizer) has been tested in Phase I clinical 
trials, but was withdrawn by the reason remains undisclosed. An RNF31 inhibitor has been 
used in a pre-clinical study of diffuse large B-cell lymphoma (DLBCL) [113]. This inhibitor 
could also be tested in breast cancer in future studies. The exploitation of RNF31 and PAK4 
specific inhibitors may offer us another choice to cancer therapeutics. 
In paper IV, the role of PAK4 in breast cancer metastasis has not been analyzed, because no 
lung metastasis has been found in this study. This may be because of the strain specificity or 
because the endpoint time we set is relatively early. As PAK4 has been shown have important 
functions in cell adhesion and motility, it would be interesting to use an alternative model to 
study metastasis in vivo.  
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